Loading clinical trials...

Pemetrexed or Docetaxel With or Without Erlotinib in Stage IIIB or Stage IV Non-Small Cell Lung Cancer | Clinical Trials | Clareo Health

COMPLETEDPHASE2

Pemetrexed or Docetaxel With or Without Erlotinib in Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Randomized Phase II Trial, Comparing Standard of Care Chemotherapy (Pemetrexed or Docetaxel) Plus Erlotinib to Standard of Care Chemotherapy (Pemetrexed or Docetaxel) Alone in EGFR TKI-Responsive Non-Small Cell Lung Cancer

NCT00660816•Case Comprehensive Cancer Center

View on ClinicalTrials.gov

Summary

RATIONALE: Pemetrexed disodium and erlotinib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. It is not yet known whether giving pemetrexed disodium or docetaxel together with erlotinib hydrochloride is more effective than giving pemetrexed disodium or docetaxel alone in treating non-small lung cancer. PURPOSE: This randomized phase II trial is studying how well giving pemetrexed disodium or docetaxel together with or without erlotinib hydrochloride works in treating patients with stage IIIB or stage IV non-small cell lung cancer.

Detailed Description

OBJECTIVES: Primary * To evaluate whether maintenance erlotinib hydrochloride added to standard of care (pemetrexed disodium or docetaxel) chemotherapy in patients with erlotinib hydrochloride-responsive advanced non-small cell lung cancer leads to an improved progression-free survival as compared to standard of care pemetrexed disodium or docetaxel alone. Secondary * To evaluate the effect of maintenance erlotinib hydrochloride on the response rate to standard of care (pemetrexed disodium or docetaxel) therapy in patients with erlotinib hydrochloride-responsive advanced non-small cell lung cancer as compared to standard of care (pemetrexed disodium or docetaxel) alone. * To evaluate whether maintenance erlotinib hydrochloride added to standard of care (pemetrexed disodium or docetaxel) chemotherapy in patients with erlotinib hydrochloride-responsive advanced non-small cell lung cancer leads to an improved overall survival as compared to standard of care (pemetrexed disodium or docetaxel) alone. * To evaluate the effect of maintenance erlotinib hydrochloride on the disease stabilization (complete response \[CR\] + partial response \[PR\] + stable disease \[SD\]) rate to standard of care (pemetrexed disodium or docetaxel) therapy in patients with erlotinib hydrochloride-responsive advanced non-small cell lung cancer as compared to standard of care (pemetrexed disodium or docetaxel) alone. * To evaluate the utility of early positron emission tomography (PET) scanning (baseline versus 1 cycle of protocol therapy) on overall disease assessment and prediction of treatment responsiveness. OUTLINE: This is a multicenter, randomized study. Patients are stratified according to lifetime smoking status (never vs ever) and ECOG performance status (0-1 vs ≥ 2). Patients are randomized to 1 of 2 treatment arms. * Arm I: (standard of care alone): Patients receive pemetrexed disodium intravenously (IV) over 10 minutes OR docetaxel IV over 60 minutes on day 1. Treatment repeats every 21 days for up to 8 courses in the absence of disease progression or unacceptable toxicity. * Arm II: (standard of care plus erlotinib): Patients receive pemetrexed disodium IV over 10 minutes OR docetaxel IV over 60 minutes on day 1 and erlotinib hydrochloride orally (PO) once daily on days 2-19. Treatment repeats every 21 days for up to 8 courses in the absence of disease progression or unacceptable toxicity. Patients may continue to receive standard chemotherapy with or without erlotinib hydrochloride in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up every 8 weeks.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Pathologic diagnosis of stage IIIB (with pleural effusion) or IV non-small cell lung cancer
•Progression following at least twelve weeks of treatment with single-agent erlotinib (or in combination with other experimental agents) during which time the patients experienced a clinical benefit as assessed by his/her treating physician and corroborated by radiographic assessment (at least one CT scan following at least 4 weeks of erlotinib monotherapy demonstrating stable disease or response on erlotinib therapy).
•At least one measurable lesion as defined by modified Response Evaluation Criteria In Solid Tumors (RECIST) criteria
•Eastern Cooperative Oncology Group (ECOG) performance status of 0-2
•Life expectancy of at least 12 weeks
•Absolute neutrophil count (ANC) \>= 1.5x10(9)/L
•Platelet count \>= 100x 10(9)
•Hemoglobin \>= 8.0 g/dl
•Serum creatinine =\< 1.5 upper limit of normal OR calculated creatinine clearance \>= 45 mL/min
•Total bilirubin =\< 1.5 x upper limit of normal (ULN)
+5 more criteria

Exclusion Criteria

•Active central nervous system disease (CNS) metastases, as indicated by clinical symptoms, cerebral edema or progressive growth (subjects with a clinical history of CNS metastases or cord compression are allowable if they have been definitively treated and are clinically stable for at least 4 weeks before first dose of study treatment for prior whole brain radiation and 2 weeks for prior gamma knife therapy)
•More than 1 prior cytotoxic chemotherapy regimen for relapsed or metastatic disease (not including erlotinib)
•Any prior epidermal growth factor receptor (EGFR) inhibitor therapy except for erlotinib
•Major surgery, chemotherapy, or investigational agents within 3 weeks of treatment day 1 (except for erlotinib). Radiation therapy within 2 weeks of treatment day 1 (except for erlotinib).
•Prior treatment with both pemetrexed and docetaxel chemotherapy
•Pregnancy or breastfeeding or not receiving adequate contraception (including the patients spouse)
•Other severe acute or chronic medical or psychiatric conditions or laboratory abnormality that may increase the risk associated with study participation or study drug administration or may interfere with the interpretation of study results, and in the judgment of the investigator would make the patient inappropriate for entry into this study
•Patients who must receive pemetrexed and have the presence of third space fluid which cannot be controlled by drainage
•Patients who must receive docetaxel and who have peripheral neuropathy \> grade 2
•Patients who must receive docetaxel and who have had a hypersensitivity reaction to medications formulated with polysorbate 80

Locations (13)

Wayne State University

Detroit, Michigan, United States

Columbia Presbyterian

New York, New York, United States

Lake/University Ireland Cancer Center